Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 208

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 208
---
 requires the development of estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option -basedtechniques are highly volatile and sensitive to changes in the trading market price of the Company’s common stock. Because liability -classifiedfinancial instruments are initially and subsequently carried at fair value, the Company’s financial results will reflect the volatility in these estimate and assumption changes. Changes in fair value are recognized as a component of other (expense) income in the consolidated statements of operations.

F-22 REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 10. Warrants (cont.) At the date of issuance, the Company valued the Class C Common Stock Warrants using a Monte -Carlosimulation model with a fair value of $14.0 million. As of December 31, 2024, the Company has received notices of alternative cashless exercises for 6,217,640 Class C Common Stock Warrants issued in connection with the February 2023 Public Offering for 5,160shares of common stock. As of December 31, 2024, the Company re -valued232,360 outstanding Class C Common Stock Warrants to purchase up to 485shares of common stock using a Monte -Carlosimulation model with a fair value of $2,246. For year ended December 31, 2024, the gain of $0.1 million, resulting from the change in the fair value of the liability for the unexercised warrants was recorded as a change in fair value of the warrant liability in the accompanying consolidated statements of operations. As part of the Class D Warrant Inducement on August 22, 2024, the exercise price of the Class C Common Stock Warrants was reset from $38.24 to $16.00. Class D Pre-Funded Warrants In connection with the February 2024 Public Offering, the Company issued pre -fundedwarrants to purchase up to 77,282shares of common stock at an exercise price of $0.0016 per share. Between February 5, 2024 and February 13, 2024, the Company received notices of cash exercise for the Class D Pre -FundedWarrants issued in connection with the February 2024 Public Offering for 77,282shares of common stock at a total purchase price of $123.65. As of December 31, 2024, there were no Class D